Event Welcome
Welcome and Introduction
Plenary Session
Session 1: Detect, Screen and Diagnose
- General diagnosis overview
- When to suspect cardiac amyloidosis
- Screening algorithms and decision support tools
Breakout
The Next Frontier in Amyloidosis Management: Comprehensive CMR Imaging Strategies for Improved Patient Outcomes
Agenda
Welcome and Introduction
Clinical integration of Cardiac MRI: the UK Academic experience
Clinical integration of Cardiac MRI: Community insights from US
Audience questions and closing remarks
Learning Objectives
Determine the value of cardiac MRI for evaluating cardiac amyloidosis.
Identify CMR features consistent with amyloidosis.
Recall patient characteristics suggestive of amyloidosis and warrant assessment with CMR.
This breakout is sponsored by Circle Cardiovascular Imaging.
Plenary Session
Session 2: Detect, Screen and Diagnose
-
Imaging masterclass 1 Assessing structure and function: Transthoracic echo with case example
-
Imaging masterclass 2 Tissue characterisation: MRI with case example
-
Imaging masterclass 3 Definitive diagnosis: Optimal techniques for scintigraphy
-
Genotype and genetic testing
Plenary Session
Setting up a Multidisciplinary Amyloidosis Centre: The Neurologist Perspective
Plenary Session
Session 3: Management of CA and its Sequelae
- Management of AL cardiomyopathy: The importance of a haematology cardiology interaction
- ATTR management: TTR stabilisers and silencers
- Future disease modifying therapy for ATTR
IME Symposium
ATTR-CM: Where Are We Now and Where to Next?
Agenda
-
Welcome and Introduction
-
Presentation: Measuring Success in ATTR-CM: Now and in the Future
-
Presentation: Is reversal within reach?
-
Audience questions and closing remarks
Learning Objectives
-
Recall what the current ATTR-CM therapy landscape is in terms of clinical efficacy
-
Quantify the current need to reverse CM disease in terms of progressive disease and mortality rate
-
Describe the process of antibody-mediated disease reversal
This IME symposium is supported by an unrestricted educational grant from AstraZeneca.
Plenary Session
Session 4: Management of CA and its Sequelae
- HF & Arrhythmia management: AF, AV nodal disease, ventricular arrhythmias
- Treatment success: Clinical and patient reported outcomes
Event Close
Closing remarks
Rodney Falk
Course Director
Brigham and Women's Hospital, Boston, US
more info
Timothy Albert
Circle Cardiovascular Imaging, Calgary, CA
Kevin Alexander
Stanford University School of Medicine, Stanford, US
Sarah Cuddy
Brigham and Women's Hospital, Boston, US
Sharmila Dorbala
Brigham and Women's Hospital, Boston, US
Marianna Fontana
University College London, London, UK
Julian Gillmore
University College London, London, UK
Finn Gustafsson
University of Copenhagen, Copenhagen DK
Philip Hawkins
University College London, London, UK
Isabelle Lousada
Amyloidosis Research Consortium, Newton, US
Ana Martinez-Naharro
Royal Free London NHS Foundation Trust, London, UK
Ahmed Masri
Oregon Health & Science University Medical Group, Portland, USA
Kanae Mukai
Salinas Valley Health, California, US
Laura Obici
I.R.C.C.S. San Matteo Polyclinic, Pavia, IT
Sven Plein
University of Leeds, Leeds, UK
Márcia Waddington-Cruz
Federal University of Rio de Janeiro, Rio de Janeiro, BR
